Liegner, K.B. (2019) Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases. Antibiotics (Basel), 8, 72.
https://doi.org/10.3390/antibiotics8020072

has been cited by the following article:

• TITLE: Antabuse for Lyme Disease: The Way Forward

  AUTHORS: David S. Younger, Beverley F. Murphy

  KEYWORDS: Disulfiram, Antabuse, Lyme Disease, Immune Globulin Therapy

  JOURNAL NAME: World Journal of Neuroscience, Vol.10 No.1, November 29, 2019

  ABSTRACT: Despite leadership by dedicated lay organization and patient-based advocacy groups, the way forward for prospective candidates for disulfiram treatment has been difficult. This article provides the background, overview of disulfiram, in particular its intended use in post-treatment Lyme disease syndrome after a standard of care course of antibiotics fails to alleviate symptoms of tick borne disease. A series of recommendations are offered to guide patients and clinicians.